MedTrace Logo

Routine Application of Ostenil® Mini in Patients with Rhizarthrosis

NCT03879434 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2024-10-09

No results posted yet for this study

Summary

PMCF study to observe the routine application of Ostenil® Mini in the treatment of pain and restricted mobility in degenerative and traumatic changes of the CMC joint.

Conditions

  • Rhizarthrosis

Interventions

DEVICE

Ostenil® Mini

Ostenil® Mini is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 1.0 % sodium hyaluronate from fermentation

Sponsors & Collaborators

  • TRB Chemedica AG

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-17
Primary Completion
2024-05-16
Completion
2024-05-16

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03879434 on ClinicalTrials.gov